Literature DB >> 32448690

Commentary: Rethinking surgical protocols in the COVID-19 era.

Daniel T Engelman1, Rakesh C Arora2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32448690      PMCID: PMC7153524          DOI: 10.1016/j.jtcvs.2020.04.015

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


× No keyword cloud information.
Daniel T. Engelman, MD, and Rakesh C. Arora, MD, PhD In the current era of the SARS-CoV-2 (ie, COVID-19) pandemic, routine preoperative nasal swabbing for identification of Staph carriers in our patient population should be reconsidered. See Letter page e39. In the current era of the severe acute respiratory syndrome coronavirus 2 (ie, coronavirus disease 2019 [COVID-19]) pandemic, the Centers for Disease Control and Prevention recently published recommendations for the care of our patients. There were additional modifications provided by the American College of Surgeons particularly pertinent to surgical patients and personnel. Both organizations have recommended stopping elective cases and to implement logical, tiered general precautions, but there has been less granular guidance addressing specific aspects of perioperative care and management. Although by and large the surgical community has complied with this request, the infectious risk of COVID-19 and its life-threatening complications remains a reality for those patients requiring urgent/emergency surgery and for the surgeons and health care professionals who perform these operations. In this issue of the Journal, Mayeur and colleagues suggest that the routine practice of nasal screening for Staphylococcus aureus before surgery may compromise health care professional safety during the swabbing and testing process. Routine universal decontamination using intranasal povidone–iodine has been shown to decrease the surgical-site infection rate by more than 50% among patients undergoing elective orthopedic surgery, and as such under normal circumstances, this would seem a prudent approach in cardiac surgical patients. With inadvertent transmission of COVID-19 as a possible consideration, it is imperative to reduce potential risk of infection to our health care workers, perhaps our most precious resource in our anti-COVID-19 armamentarium. Logic dictates that until a more critical assessment is made of the risk posed by this practice, routine preoperative nasal swabbing for the identification of Staph carriers in our patient population should be reconsidered. The risk of bacterial resistance with routine, rather than selective, nasal decontamination is far outweighed by the advantage of avoiding any additional COVID-19 infection risk in our health care workers. Thus, we suggest the routine decontamination of all patients needing urgent/emergent procedures, without preoperative testing to determine colonization.
  3 in total

1.  Ramping Up Delivery of Cardiac Surgery During the COVID-19 Pandemic: A Guidance Statement From The Society of Thoracic Surgeons COVID-19 Task Force.

Authors:  Daniel T Engelman; Sylvain Lother; Isaac George; Gorav Ailawadi; Pavan Atluri; Michael C Grant; Jonathan W Haft; Ansar Hassan; Jean-Francois Legare; Glenn Whitman; Rakesh C Arora
Journal:  Ann Thorac Surg       Date:  2020-05-12       Impact factor: 4.330

2.  A 48-Year-Old Man at Low Risk for SARS-CoV-2 Infection Who Underwent Planned Elective Triple-Vessel Coronary Artery Bypass Graft Surgery at a National Heart Center in Indonesia Followed by a Fatal Case of COVID-19.

Authors:  Tri Wisesa Soetisna; Andhika Citra Buana; Edward Suryadi Tirta; Ardiyan Ardiyan; Dicky Aligheri; Bagus Herlambang; Amin Tjubandi; Dudy Arman Hanafy; Sugisman Sugisman
Journal:  Am J Case Rep       Date:  2021-01-25

3.  Literature-based considerations regarding organizing and performing cardiac surgery against the backdrop of the coronavirus pandemic.

Authors:  Tomasz Dziodzio; Mariusz Kuśmierczyk; Andrzej Juraszek; Jarosław Kuriata; Piotr Kołsut; Tomasz Hryniewiecki; Monika Różewicz-Juraszek
Journal:  J Cardiothorac Surg       Date:  2021-04-09       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.